Mabvax Therapeutics Holdings Inc Stock Nasdaq
Equities
US55414P5044
Biotechnology & Medical Research
Sales 2016 | 148K 202K | Sales 2017 | - | Capitalization | 14.41M 19.71M |
---|---|---|---|---|---|
Net income 2016 | -17M -23.25M | Net income 2017 | -19M -25.98M | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K 643K | Net Debt 2017 | 2.48M 3.39M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 14-07-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 14-07-07 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |